<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03414268</url>
  </required_header>
  <id_info>
    <org_study_id>AIPF007</org_study_id>
    <nct_id>NCT03414268</nct_id>
  </id_info>
  <brief_title>Micronized dHACM Injectable for the Treatment of Plantar Fasciitis</brief_title>
  <official_title>A Phase 3, Prospective, Double-Blinded, Randomized Controlled Trial of the Micronized dHACM Injection As Compared To Saline Placebo Injection In The Treatment Of Plantar Fasciitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MiMedx Group, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MiMedx Group, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, double-blinded, randomized controlled trial of the micronized dHACM injection as&#xD;
      compared to the saline placebo injection in the treatment of plantar fasciitis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 276 patients will be enrolled in this study. Each patient will receive 1&#xD;
      injection and be evaluated for efficacy and safety during a 6-month observation period.&#xD;
      Randomization will be 1:1. The study is expected to be completed within 34 months, inclusive&#xD;
      of enrollment and follow-up of all subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 8, 2018</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in VAS score</measure>
    <time_frame>90 Days</time_frame>
    <description>Visual Analog Scale for Pain:</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>180 Days</time_frame>
    <description>The incidence of related Adverse Events (AEs), Serious Adverse Events (SAEs), and Unanticipated Adverse Events during the first 12 months post injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Foot Function Index - Revised (FFI-R) (Short Form)</measure>
    <time_frame>90 Days</time_frame>
    <description>Foot Function Index - Revised: Patient Reported Questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">276</enrollment>
  <condition>Fasciitis, Plantar</condition>
  <arm_group>
    <arm_group_label>Micronized dHACM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection of 1mL 0.9% Sodium Chloride Injection, USP</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Micronized dHACM</intervention_name>
    <description>1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)</description>
    <arm_group_label>Micronized dHACM</arm_group_label>
    <other_name>dHACM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Injection</intervention_name>
    <description>Injection of 1mL 0.9% Sodium Chloride Injection, USP</description>
    <arm_group_label>Saline Injection</arm_group_label>
    <other_name>0.9% NaCl</other_name>
    <other_name>Normal Saline</other_name>
    <other_name>Sodium Chloride Injection, USP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of plantar fasciitis for ≥ 1 month (30 days) and ≤ 18 months by&#xD;
             the investigator&#xD;
&#xD;
          2. VAS Pain scale of ≥ 45 mm at randomization&#xD;
&#xD;
          3. Plantar fasciitis with conservative treatment for ≥ 1 month (30 days), including any&#xD;
             of the following modalities:&#xD;
&#xD;
               -  RICE&#xD;
&#xD;
               -  Stretching exercises&#xD;
&#xD;
               -  NSAIDs&#xD;
&#xD;
               -  Orthotics&#xD;
&#xD;
          4. Diagnostic X-Ray within 6 months of enrollment showing view of calcaneus negative for&#xD;
             calcaneal fracture or structural abnormalities&#xD;
&#xD;
          5. BMI ≤ 40 kg/m2&#xD;
&#xD;
          6. Age ≥ 21 years and &lt; 80 years&#xD;
&#xD;
          7. Ability to sign Informed Consent and Release of Medical Information Forms&#xD;
&#xD;
          8. Ability to receive and respond to text messages or emails on a daily basis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior surgery or trauma to the affected site&#xD;
&#xD;
          2. Subjects requiring bilateral plantar fasciitis treatment at time of enrollment&#xD;
&#xD;
          3. Prior use of any lower limb injection therapy, including corticosteroids or PRP in&#xD;
             either limb within the last 3 months&#xD;
&#xD;
          4. Has diabetes either Type I or Type II.&#xD;
&#xD;
          5. Systemic disorders associated with enthesopathy (disorder of entheses, i.e. bone&#xD;
             attachments) such as Gout, Reiter's syndrome, rheumatoid arthritis, etc.&#xD;
&#xD;
          6. The presence of diagnosed comorbidities that can be confused with or can exacerbate&#xD;
             the condition- to be assessed by X-ray - including but not limited to:&#xD;
&#xD;
               -  Calcaneal stress fracture&#xD;
&#xD;
               -  Nerve entrapment syndrome (diagnosed as Baxter Nerve Syndrome)&#xD;
&#xD;
               -  Fat pad atrophy&#xD;
&#xD;
               -  Acute traumatic rupture of the plantar fascia&#xD;
&#xD;
               -  Calcaneal tumor&#xD;
&#xD;
               -  Tarsal tunnel syndrome (diagnosed)&#xD;
&#xD;
               -  Significant bone deformity of the foot that may interfere with the study&#xD;
&#xD;
          7. Affected site exhibits clinical signs and symptoms of infection&#xD;
&#xD;
          8. Known allergy or known sensitivity to Aminoglycosides&#xD;
&#xD;
          9. Subjects who are non-ambulatory&#xD;
&#xD;
         10. History of more than 14 days treatment with immuno-suppressants (including systemic&#xD;
             corticosteroids) or cytotoxic chemotherapy within 30 days prior to enrollment, or who&#xD;
             are anticipated to require such medications during the course of the study&#xD;
&#xD;
         11. Prior radiation at the site&#xD;
&#xD;
         12. Use of any investigational drug(s) or therapeutic device(s) within 3 months preceding&#xD;
             enrollment&#xD;
&#xD;
         13. Immune disorders including Systemic Lupus Erythematosus (SLE), Fibromyalgia, Acquired&#xD;
             Immunodeficiency Syndrome (AIDS) or Human Immunodeficiency Virus (HIV)&#xD;
&#xD;
         14. History of any condition (including drug or alcohol abuse, medical or psychiatric&#xD;
             condition) that is likely to impair understanding of or compliance with the study&#xD;
             protocol, in the judgment of the investigator&#xD;
&#xD;
         15. Pregnancy at enrollment or within last 6 months, women who are breastfeeding, or women&#xD;
             of childbearing potential who are planning to become pregnant during the time of the&#xD;
             study OR are unwilling/unable to use acceptable methods of contraception (birth&#xD;
             control pills, barriers, or abstinence)&#xD;
&#xD;
         16. Workers' compensation subjects&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart D Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MedStar Union Memorial Hospital, Baltimore, MD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern Arizona VA Health Care System</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ILD Research Center</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Research</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limb Preservation Platform, Inc.</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizon Clinical Research</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foot and Ankle Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Five Cities Foot Clinic</name>
      <address>
        <city>Pismo Beach</city>
        <state>California</state>
        <zip>93449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Pines VA Healthcare System</name>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <zip>33744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulfcoast Research Institute, LLC</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctors Research Network</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Podiatry</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Foot &amp; Ankle Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Orthopedics Center</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Orthopedics Center</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Futuro Clinical Trials, LLC</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endeavor Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Podiatry</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2018</study_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic plantar fasciitis</keyword>
  <keyword>Heel pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fasciitis</mesh_term>
    <mesh_term>Fasciitis, Plantar</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

